Yang, X.; Wu, S.; Dou, Z.; Dong, Y.; Dai, J.
L-Arginine-Modified Chitosan Curcumin Nanocrystals Target M1 Macrophages via CAT-2/Clathrin-Mediated Endocytosis for Mitochondrial Protection and ALI/ARDS Therapy. Pharmaceutics 2026, 18, 425.
https://doi.org/10.3390/pharmaceutics18040425
AMA Style
Yang X, Wu S, Dou Z, Dong Y, Dai J.
L-Arginine-Modified Chitosan Curcumin Nanocrystals Target M1 Macrophages via CAT-2/Clathrin-Mediated Endocytosis for Mitochondrial Protection and ALI/ARDS Therapy. Pharmaceutics. 2026; 18(4):425.
https://doi.org/10.3390/pharmaceutics18040425
Chicago/Turabian Style
Yang, Xiaowen, Shiyue Wu, Zhiya Dou, Yuxiao Dong, and Jundong Dai.
2026. "L-Arginine-Modified Chitosan Curcumin Nanocrystals Target M1 Macrophages via CAT-2/Clathrin-Mediated Endocytosis for Mitochondrial Protection and ALI/ARDS Therapy" Pharmaceutics 18, no. 4: 425.
https://doi.org/10.3390/pharmaceutics18040425
APA Style
Yang, X., Wu, S., Dou, Z., Dong, Y., & Dai, J.
(2026). L-Arginine-Modified Chitosan Curcumin Nanocrystals Target M1 Macrophages via CAT-2/Clathrin-Mediated Endocytosis for Mitochondrial Protection and ALI/ARDS Therapy. Pharmaceutics, 18(4), 425.
https://doi.org/10.3390/pharmaceutics18040425